Wednesday, July 8, 2026

pharma · Diabetic Macular Edema · Non-infectious Uveitis Affecting the Posterior Segment of the Eye · ANIP

ANI PHARMACEUTICALS

ANI PHARMACEUTICALS clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

500 Alexander Park, Princeton, New Jersey 08540, US HQ
678 Employees
Public company Type
ANIP · NYSE Ticker
Company details
Status
Public
HQ
500 Alexander Park, Princeton, New Jersey 08540, US
Employees
678
Programs
11
Drugs
7
Patents
7
Intelligence · Clinical Programs

ANI PHARMACEUTICALS projects

2 ClinicalTrials.gov programs sponsored by ANI PHARMACEUTICALS.

ANI PHARMACEUTICALS has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Fluocinolone Acetonide

    ANI PHARMACEUTICALS INC

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial
  2. Fluocinolone Acetonide

    ANI PHARMACEUTICALS INC

    Macular Edema

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does ANI PHARMACEUTICALS have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.